Here’s a quick tracking of the state-level bills for psychedelics regulations currently under discussion, as of April 21:
-
North Carolina: HB727 would create a $5-million grant fund to expand psychedelic research. As of August 2024, the state’s Health Department will accept applications focusing on “breakthrough therapies” — psilocybin for anxiety, depression and pain management; and MDMA for PTSD for military veterans, first responders, frontline health workers and people who suffered domestic violence or sexual assault. Funding would be provided for three years of research.
-
Washington: Multi-amended SB5263 promoting psilocybin research and a new pilot program for military veterans and first responders with PTSD and SUDs has received the Senate’s final approval and was sent to Gov. Jay Inslee (D) on April 20.
-
Hawaii: HB1340 creates an advisory council for potential regulations for legal access to psilocybin and MDMA once federally approved. The bill was amended and approved in full-chamber Senate and headed back to the House for concurrence, where the chamber expressed disagreement with the changes. Discussions are ongoing.
-
Nevada: Amended SB242, which will now solely create a psychedelics working group, got the Senate’s approval on April 13 and is now heading toward the full chamber.
-
Massachusetts: HB3574 rescheduling MDMA and making it available for PTSD treatment following FDA approval with a $5,000 cap was sent by the House to the Public Health joint committee, with Senate concurrence on April 18.
-
Iowa: HF240 removing psilocybin and psilocin from the state’s list of controlled substances as Schedule I drugs is pending at the House public safety committee, where the subcommittee has unanimously recommended its passage.
-
Photo: Benzinga edit with photo by Alexander_Volkov and canbedone on Shutterstock.